The reason given is that, although initial clinical trials showed promise in preventing serious Covid infections in immunocompromised and vaccine-nonresponsive people, more recent laboratory studies report that Evusheld may not effectively prevent infection with most of the variants currently circulating.

The report states

“Because of the lack of evidence of clinical effectiveness, the cost-effectiveness estimates for tixagevimab plus cilgavimab (Evusheld) are highly uncertain. They are also likely to be much higher than what NICE considers an acceptable use of NHS resources”.

MDS UK recognises that many of our members will be very disappointed with this outcome and we will be working with other Blood Cancer charities, through the Blood Cancer Alliance, to determine what can be done to improve protection for the affected groups.

*** From 14th June 2023 Evusheld is not available as a Covid treatment in Scotland. For more information click here ***